Asenapine.
Asenapine is a novel psychopharmacological agent that binds with high affinity and specificity to numerous dopamine, serotonin, noradrenaline (norepinephrine) and histamine receptor subtypes. It is being developed for the treatment of schizophrenia and bipolar mania. In two randomized, controlled trials of asenapine monotherapy and in one randomized, controlled trial of adjunctive asenapine therapy in adult patients with bipolar I disorder, sublingual asenapine produced significantly greater reductions from baseline than placebo in clinician-assessed Young Mania Rating Scale (YMRS) total score at 3 weeks. In two randomized, controlled trials in adult patients with acute schizophrenia, treatment with asenapine reduced from baseline the clinician-assessed Positive and Negative Syndrome Scale (PANSS) total score to a significantly greater extent than placebo at 6 weeks. In schizophrenic patients with predominant, persistent, negative symptoms, asenapine at 26 weeks reduced the Negative Symptom Assessment (NSA-16) total score from baseline to an extent similar to that observed with olanzapine. Sublingual asenapine was generally well tolerated in clinical trials, with most treatment-emergent adverse events being of mild to moderate severity. Incidence rates of clinically significant weight gain, extrapyramidal symptoms, hyperprolactinaemia and alterations in glucose or lipid metabolism were generally low.
Weber
Juliane
J
Wolters Kluwer Health, Adis, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand.
McCormack
Paul L
PL
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings; C522667:asenapine
Psychopharmacology (Berl). 2008 May;198(1):103-11
18297468
Psychopharmacol Bull. 2007;40(2):41-53
17514185
Pharmacoeconomics. 2008;26(2):149-62
18198934
Psychopharmacology (Berl). 1997 Jun;131(4):339-45
9226735
N Engl J Med. 2005 Sep 22;353(12):1286-8
16172204
Synapse. 2009 May;63(5):413-20
19177511
Pharmacoeconomics. 2005;23(6):583-94
15960554
Drugs. 2008;68(16):2269-92
18973393
Eur Neuropsychopharmacol. 2009 Mar;19(3):177-87
19116183
J Psychopharmacol. 2010 Mar;24(3):341-8
18719049
N Engl J Med. 2005 Sep 22;353(12):1209-23
16172203
J Psychopharmacol. 2009 Jan;23(1):65-73
18308814
CNS Drugs. 2006;20(5):389-409
16696579
Psychopharmacology (Berl). 2009 Jun;204(2):251-64
19198810
Psychopharmacology (Berl). 2008 Feb;196(3):417-29
17940749
J Clin Psychiatry. 2007 Oct;68(10):1492-500
17960962
Neuropsychopharmacology. 2008 Nov;33(12):2934-45
18418367